Nuformix Proposes Biovara Acquisition for Respiratory Assets

The share-for-share merger would combine Biovara's LipAprep with Nuformix's NXP002 programme for fibrotic lung disease.

Updated on Nov. 11, 2026 in Asthma

Nuformix Proposes Biovara Acquisition for Respiratory Assets

Nuformix, a drug development company focused on fibrosis and oncology, has proposed acquiring Biovara, a privately owned UK pharmaceutical developer focused on respiratory conditions, in a merger of equals through a share-for-share exchange. The combined company would hold two proprietary assets: LipAprep and NXP002.

Why it matters

The proposed deal would create a clinical-stage respiratory drug developer with two differentiated assets, including a programme with Orphan Drug Designation in the US and Europe. Combining the assets could make the enlarged group a more attractive development and partnering proposition.

A controlled clinical study found aprepitant reduced 24-hour cough frequency by over 30% versus placebo after three days of dosing at the standard antiemetic dose. The study's sample size and the durability of this effect beyond three days were not reported.

The players

Nuformix

Nuformix is a pharmaceutical development company focused on fibrosis and oncology through drug repurposing.

Biovara

Biovara is a privately owned UK pharmaceutical development company focused on respiratory conditions.

The details

Biovara's lead asset, LipAprep, is developed to treat lung cancer-related cough and has completed phase 1 single-dose clinical development. It is being advanced toward a phase 2 proof-of-concept study, while NXP002 targets idiopathic pulmonary fibrosis and other fibrotic interstitial lung diseases.

Timeline

  1. November 11, 2026: Nuformix's proposed acquisition of Biovara was reported.

Health Landscape

Orphan Drug Designation in the US and Europe is a regulatory status granted to therapies for rare conditions, and NXP002 holds it in both jurisdictions. The proposed deal positions the combined company's fibrosis programme within that incentive framework alongside its cough-focused asset.

For patients with lung cancer-related cough or fibrotic lung disease, the proposed deal could eventually expand treatment options, though LipAprep is only at phase 1 and NXP002's clinical path is not described. No change to available treatment is reported at this stage.

The takeaway

Proposed mergers of early-stage drug developers often hinge on whether combined assets advance through clinical testing, so readers should watch for the phase 2 progress of LipAprep and the completion status of the deal.

Further reading

For more on respiratory drug development, explore our Asthma coverage.

Source note: This article includes information reported by PMLive.